Because the sensor is placed directly into the bloodstream, researchers are now able to detect instantaneous changes in blood glucose, body temperature, and activity for 28 days or longer while reducing animal stress and measurement variability commonly associated with the use of glucose test strips.

"We are excited to release the HD-XG glucose implant because it allows researchers to observe indicators of diabetes and metabolic diseases as they develop," said DSI CEO Bert Harman. "Adoption of continuous glucose telemetry in research studies will result in a more sophisticated understanding of blood glucose levels and, ultimately, the development of better drugs, devices, and therapies for humans."

The Centers for Disease Control and Prevention (CDC) estimates that diabetes affects 26 million people in the U.S. alone, or 8.3 percent of the population. Diabetes is a major cause of heart disease, stroke, kidney failure, lower-limb amputations, and blindness. The National Institutes of Health (NIH) is providing an estimated $1 billion in funding for diabetes research in 2014. In addition, with nearly every major pharmaceutical company engaged in the development of new treatments for diabetes and metabolic disease, demand for better research instrumentation has also increased.

ABOUT DSIDSI is a pioneering biomedical research company focused on preclinical systems physiology and pharmacology. The recognized global leader in physiologic monitoring, DSI offers telemetry, instrumentation, software and services that help advance science. DSI serves many industries including: Pharmaceuticals, Academia, Contract Research Organizations, Biological and Chemical Defense, the Medical Device Industry, Government, and Biotechnology companies. Solutions are tailored specifically to meet the unique research needs of their customers.